Castle Biosciences study finds 83% of atopic dermatitis patients interested in molecular testing to guide systemic therapy choice

By Public Technologies
  • Castle Biosciences highlighted a newly published patient-and-caregiver study on atopic dermatitis treatment selection, reinforcing demand for its AdvanceAD-Tx test.
  • Results were already presented via publication in Dermatology and Therapy, not slated for a future medical meeting.
  • Survey responses pointed to frequent therapy changes tied to unmet treatment goals, underscoring inconsistent real-world control on current options.
  • Most respondents signaled strong interest in molecular testing to help choose a systemic therapy, supporting adoption potential for AdvanceAD-Tx.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609241630PR_NEWS_USPR_____DA56487) on September 24, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.